{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:16:16Z","timestamp":1772003776509,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.neuropharm.2008.06.069","type":"journal-article","created":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T09:25:46Z","timestamp":1215681946000},"page":"900-907","source":"Crossref","is-referenced-by-count":43,"title":["Flavan-3-ol derivatives are positive modulators of GABAA receptors with higher efficacy for the \u03b12 subtype and anxiolytic action in mice"],"prefix":"10.1016","volume":"55","author":[{"given":"Sebastian P.","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth N.","family":"Mewett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane R.","family":"Hanrahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Chebib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham A.R.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2008.06.069_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0891-5849(02)01137-1","article-title":"Uptake and metabolism of epicatechin and its access to the brain after oral ingestion","volume":"33","author":"Abd El Mohsen","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1098-2299(199706)41:2<99::AID-DDR7>3.0.CO;2-M","article-title":"6-Methylflavone, a benzodiazepine receptor ligand with antagonistic properties on rat brain and human recombinant GABAA receptors in vitro","volume":"41","author":"Ai","year":"1997","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/sj.bjp.0703335","article-title":"Activation and block of recombinant GABA(A) receptors by pentobarbitone: a single-channel study","volume":"130","author":"Akk","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/13543784.14.5.601","article-title":"The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics","volume":"14","author":"Atack","year":"2005","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2008.06.069_bib5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.105.089920","article-title":"TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for \u03b12 and \u03b13-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates","volume":"316","author":"Atack","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrn1703","article-title":"Neurosteroids: endogenous regulators of the GABAA receptor","volume":"6","author":"Belelli","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib7","first-page":"93","article-title":"What is synergy?","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00470579","article-title":"Benzodiazepine antagonist RO 15-1788: neurological and behavioral effects","volume":"78","author":"Bonetti","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2008.06.069_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-2999(03)01274-3","article-title":"The mouse light\/dark box test","volume":"463","author":"Bourin","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib10","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra021261","article-title":"Mechanisms of actions of inhaled anesthetics","volume":"348","author":"Campagna","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib11","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.bcp.2004.07.022","article-title":"The dietary flavonoids apigenin and (\u2212)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABAA receptors","volume":"68","author":"Campbell","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0091-3057(81)90007-1","article-title":"Neuropharmacological specificity of a simple animal model for the behavioral actions of benzodiazepines","volume":"15","author":"Crawley","year":"1981","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrn1625","article-title":"Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors","volume":"6","author":"Farrant","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2006.04.004","article-title":"Central nervous system depressant action of flavonoid glycosides","volume":"539","author":"Fernandez","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib15","first-page":"2029","article-title":"Neuro-pharmacological studies on SB 5833, a new psychotherapeutic agent of the benzodiazepine class","volume":"24","author":"Ferrini","year":"1974","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.neuropharm.2008.06.069_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0166-4328(01)00292-3","article-title":"Factors controlling measures of anxiety and responses to novelty in the mouse","volume":"125","author":"File","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1476-5381.1985.tb08952.x","article-title":"The effects of triazolobenzodiazepines in two animal tests of anxiety and in the holeboard","volume":"86","author":"File","year":"1985","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1124\/jpet.104.067264","article-title":"Isobolographic analysis for combinations of a full and partial agonist: curved isoboles","volume":"310","author":"Grabovsky","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1113\/jphysiol.2007.132886","article-title":"Rat \u03b16\u03b22\u03b4 GABAA receptors exhibit two distinct and separable agonist affinities","volume":"581","author":"Hadley","year":"2007","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2005.02.034","article-title":"6-Methylflavanone, a more efficacious positive allosteric modulator of \u03b3-aminobutyric acid (GABA) action at human recombinant \u03b12\u03b22\u03b32L than at \u03b11\u03b22\u03b32L and \u03b11\u03b22 GABAA receptors expressed in Xenopus oocytes","volume":"512","author":"Hall","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pharmthera.2007.03.007","article-title":"Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors","volume":"116","author":"Herd","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib22","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1021\/jf011607h","article-title":"Effects of tea components on the response of GABA(A) receptors expressed in Xenopus oocytes","volume":"50","author":"Hossain","year":"2002","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(03)01344-X","article-title":"Bilobalide, a sesquiterpene trilactone from Gingko biloba, is an antagonist at recombinant \u03b11\u03b22\u03b32L GABAA receptors","volume":"464","author":"Huang","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib24","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1021\/jm000557p","article-title":"3D-QSAR model of flavonoids binding at benzodiazepine site in GABAA receptors","volume":"44","author":"Huang","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib25","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2174\/1381612054021024","article-title":"GABAA receptor channel pharmacology","volume":"11","author":"Johnston","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/sj.bjp.0705828","article-title":"The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects","volume":"142","author":"Kavvadias","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0165-6147(00)89058-6","article-title":"Neurosteroids and GABAA receptor function","volume":"16","author":"Lambert","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib29","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1073\/pnas.0502579102","article-title":"Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator","volume":"102","author":"Lippa","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2008.06.069_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.290.5489.131","article-title":"Molecular and neuronal substrate for the selective attenuation of anxiety","volume":"290","author":"L\u00f6w","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2008.06.069_bib31","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2174\/1568026023393462","article-title":"GABAA-receptor ligands of flavonoid structure","volume":"2","author":"Marder","year":"2002","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0968-0896(00)00250-9","article-title":"Molecular modeling and QSAR analysis of the interaction of flavone derivatives with the benzodiazepine binding site of the GABA(A) receptor complex","volume":"9","author":"Marder","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0166-2236(96)80023-3","article-title":"Which GABAA-receptor subtypes really occur in the brain?","volume":"19","author":"McKernan","year":"1996","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor \u03b11 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.300.1.2","article-title":"A new benzodiazepine pharmacology","volume":"300","author":"M\u00f6hler","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib36","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.bjp.0701563","article-title":"The interaction of general anaesthetics with recombinant GABAA and glycine receptors expressed in Xenopus laevis oocytes: a comparative study","volume":"122","author":"Pistis","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib37","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1124\/jpet.106.107201","article-title":"The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors","volume":"319","author":"Popik","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib38","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.neuropharm.2006.09.013","article-title":"The novel anxiolytic ELB139 displays selectivity to recombinant GABA(A) receptors different from diazepam","volume":"52","author":"Rabe","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2008.06.069_bib39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrn1496","article-title":"Molecular and neuronal substrates for general anaesthetics","volume":"5","author":"Rudolph","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coph.2005.10.003","article-title":"GABA-based therapeutic approaches: GABAA receptor subtype functions","volume":"6","author":"Rudolph","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib41","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific \u03b3-aminobutyric acid(A) receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2008.06.069_bib42","doi-asserted-by":"crossref","first-page":"41422","DOI":"10.1074\/jbc.M401354200","article-title":"Analysis of the set of GABAA receptor genes in the human genome","volume":"279","author":"Simon","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104117","article-title":"An overview of drug combination analysis with isobolograms","volume":"319","author":"Tallarida","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1476-5381.1996.tb15221.x","article-title":"Barbiturate interactions at the human GABAA receptor: dependence on receptor subunit combination","volume":"117","author":"Thompson","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib45","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1039\/a703316h","article-title":"Enantioselective synthesis of flavonoids. Part 3, trans- and cis-flavan-3-ol methyl ether acetates","volume":"1","author":"Van Rensburg","year":"1997","journal-title":"J. Chem. Soc., Perkin Trans."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib46","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/81800","article-title":"Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms","volume":"3","author":"Walters","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/156800705774322030","article-title":"Neuroactive flavonoids interacting with GABAA receptor complex","volume":"4","author":"Wang","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coph.2005.08.005","article-title":"GABA-A receptors, a viable target for novel anxiolytics?","volume":"6","author":"Whiting","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib49","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.freeradbiomed.2004.08.002","article-title":"Flavonoids and the brain: interactions at the blood-brain barrier and their physiological effects on the central nervous system","volume":"37","author":"Youdim","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2008.06.069_bib50","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0031-9422(96)00598-5","article-title":"Plant polyphenols: biologically active compounds or non-selective binders to protein","volume":"44","author":"Zhu","year":"1997","journal-title":"Phytochemistry"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390808002670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390808002670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T09:50:06Z","timestamp":1545904206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390808002670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0028390808002670"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2008.06.069","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}